Yahoo Web Search

  1. Here's Why You Should Add Thermo Fisher to Your Portfolio

    Zacks via Yahoo FinanceOct 03 13:30 PM

    Thermo Fisher Scientific Inc. TMO has been gaining investors’ confidence on consistently positive results. Also, the company has outperformed the S&P 500’s 2.3% decline during this period. The ...

  2. While big names like Pfizer, Bristol-Myers and Lilly performed relatively poorly, Amgen, AstraZeneca, AbbVie, Sanofi and Merck delivered decent earnings and sales growth. It is to be ...

  3. Pfenex Inc (NYSE: PFNX) has a key binary event coming up: mark your calendar for Oct. 7, when the FDA is scheduled to issue its verdict on the company's lead drug candidate. Through its production ...

  4. The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Bank of America (BAC), The ...

  5. All signs point to biopharmaceutical companies continuing their aggressive pursuit of acquisitions to help meet growth targets. FiercePharma reported in a recent article that, according to KMPG'S ...

  6. Novartis (NVS) Announces Data on Asthma Drugs & Kisqali

    Zacks via Yahoo FinanceOct 02 13:53 PM

    However, competition is stiff in the breast cancer market with the likes of Eli Lilly’s LLY Verzenio and Pfizer’s PFE Ibrance. 7 Best Stocks for the Next 30 Days Just released: ...

  7. Novartis AG NVS announced additional positive data from the ongoing PREVENT study on spondylitis drug, Cosentyx (secukinumab). PREVENT is an ongoing two-year randomized, double-blind, placebo-controlled ...

  8. Following the acquisition closure of GlaxoSmithKline's plant, Thermo Fisher (TMO) will continue to manufacture APIs for the same under a multi-year supply agreement.

  9. Agios Pharmaceuticals, Inc. AGIO presented detailed data from the phase III ClarIDHy study on its leukemia drug Tibsovo (ivosidenib), which is being evaluated in previously treated patients ...

  10. Dermira, Inc. DERM announced that it has started dosing in a phase III study, evaluating its monoclonal antibody candidate, lebrikizumab, in patients with moderate-to-severe atopic dermatitis ...

  1. Ad
    related to Eli Lilly